Compare Inovio Pharmaceuticals Inc (INO) vs Plby Group Inc (PLBY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Plby Group Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Plby Group Inc trades at $1.21 (market cap $139.87M). The key difference: Plby Group Inc is the larger of the two by market cap. Which is the better fit depends on your goals.
| INO | PLBY | |
|---|---|---|
Market Cap | $89.27M | $139.87M |
Sector | Health | Consumer Cyclical |
52-Week High | $2.87 | $2.71 |
52-Week Low | $1.05 | $1.11 |
Enterprise Value | $60.28M | $287.68M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
PLBY Group trades at $1.21, up 3.42% with a market cap reflecting a P/S ratio of 1.02. The company shows improving fundamentals with five consecutive quarters of positive adjusted EBITDA and narrowing losses, though it remains unprofitable with negative ROE. Technical indicators signal bearish momentum despite neutral oscillators. Recent developments include Russell index inclusion and a strategic share repurchase program.
The outlook remains cautious due to persistent net losses and high debt levels, but operational improvements and brand repositioning offer potential upside. Key risks include execution challenges in licensing growth and competitive pressures in the leisure sector. Analyst consensus is strongly bullish with 75% buy ratings, suggesting confidence in the turnaround strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →
